Vir Biotechnology, Inc. (VIR) Bundle
Understanding Vir Biotechnology, Inc. (VIR) Revenue Streams
Understanding Vir Biotechnology, Inc.’s Revenue Streams
The revenue streams of Vir Biotechnology, Inc. comprise collaboration revenue, contract revenue, and grant revenue. Below is a detailed analysis of these revenue sources.
Breakdown of Primary Revenue Sources
| Revenue Source | Q3 2024 (in thousands) | Q3 2023 (in thousands) | YTD 2024 (in thousands) | YTD 2023 (in thousands) |
|---|---|---|---|---|
| Collaboration Revenue | $(1,102) | $(4,387) | $(2,034) | $28,408 |
| Contract Revenue | $1,391 | $289 | $54,468 | $1,484 |
| Grant Revenue | $2,091 | $6,737 | $9,397 | $39,501 |
| Total Revenues | $2,380 | $2,639 | $61,831 | $69,393 |
Year-over-Year Revenue Growth Rate
The total revenue decreased from $69,393 thousand in YTD 2023 to $61,831 thousand in YTD 2024, indicating a decline of approximately 11.5%.
Contribution of Different Business Segments to Overall Revenue
In YTD 2024, the contributions from different segments are as follows:
- Collaboration Revenue: 3.3% of total revenue
- Contract Revenue: 88.0% of total revenue
- Grant Revenue: 15.2% of total revenue
Analysis of Significant Changes in Revenue Streams
The substantial decline in collaboration revenue is primarily attributed to lower profit-sharing amounts recognized under the GSK agreement. The increase in contract revenue is largely due to the recognition of deferred revenue from the GSK collaboration, amounting to $51.7 million recognized in the first quarter of 2024 when GSK’s rights to select additional pathogens under the agreement expired. Grant revenue saw a decrease due to lower recognition from agreements with BARDA and the Bill and Melinda Gates Foundation.
A Deep Dive into Vir Biotechnology, Inc. (VIR) Profitability
A Deep Dive into Vir Biotechnology, Inc.'s Profitability
Gross Profit Margin: For the nine months ended September 30, 2024, the total revenues were $61.83 million with a cost of revenue of $161,000, resulting in a gross profit of $61.67 million, which translates to a gross profit margin of approximately 99.74%.
Operating Profit Margin: The operating loss for the same period was ($470.02 million), giving an operating profit margin of (759.72%).
Net Profit Margin: The net loss attributable to the company for the nine months ended September 30, 2024, was ($417.37 million), leading to a net profit margin of (674.44%).
Trends in Profitability Over Time
Comparing year-over-year performance, the gross profit margin for the nine months ended September 30, 2023, was 99.65% on revenues of $69.39 million with a cost of revenue of $1.97 million
The operating loss for the nine months ended September 30, 2023, was ($545.29 million), reflecting a considerable increase in operational losses compared to ($470.02 million) in 2024.
Comparison of Profitability Ratios with Industry Averages
As of 2024, the average gross profit margin in the biotechnology industry is approximately 80% - 90%, showcasing that the company's gross margin significantly exceeds industry averages. The operating profit margin for the industry averages around (15%), highlighting that the company's operational efficiency is significantly below the industry standard.
Analysis of Operational Efficiency
The total operating expenses for the nine months ended September 30, 2024, were $531.85 million, comprising:
- Research and development: $400.42 million
- Selling, general, and administrative: $92.33 million
- Restructuring and impairment charges: $38.94 million
The gross margin trend indicates a consistent level of high gross profits, although the operational efficiency is hampered by rising operating expenses, particularly in research and development.
| Metric | 2024 | 2023 | Industry Average |
|---|---|---|---|
| Gross Profit Margin | 99.74% | 99.65% | 80%-90% |
| Operating Profit Margin | (759.72%) | (789.75%) | (15%) |
| Net Profit Margin | (674.44%) | (718.61%) | (10%) |
The significant variance in operating and net profit margins indicates challenges in cost management and operational efficiency, requiring strategic adjustments to align with industry standards.
Debt vs. Equity: How Vir Biotechnology, Inc. (VIR) Finances Its Growth
Debt vs. Equity: How Vir Biotechnology, Inc. Finances Its Growth
Overview of the Company's Debt Levels
As of September 30, 2024, the total liabilities of the company amounted to $257.6 million, which includes both long-term and short-term debt. The breakdown is as follows:
- Contingent consideration, noncurrent: $33.2 million
- Other long-term liabilities: $13.9 million
The total stockholders' equity was reported at $1.24 billion .
Debt-to-Equity Ratio and Comparison to Industry Standards
The debt-to-equity ratio for the company stands at approximately 0.21 (calculated as total liabilities of $257.6 million divided by total equity of $1.24 billion). This is significantly lower than the average ratio for the biotechnology industry, which typically ranges from 0.4 to 0.6 .
Recent Debt Issuances, Credit Ratings, or Refinancing Activity
In September 2024, the company completed a significant transaction involving a licensing agreement with Sanofi, which included an upfront payment of $100 million. This agreement is expected to influence future cash flows and funding strategies .
The company currently holds no credit ratings from major agencies, which is typical for clinical-stage biopharmaceutical companies that are in the research and development phase .
How the Company Balances Between Debt Financing and Equity Funding
The company has primarily relied on equity financing, evident from the reported $1.24 billion in total stockholders' equity as of September 30, 2024 . This is complemented by strategic partnerships and grants, such as those from BARDA, which provide additional funding sources without increasing debt levels.
| Financial Metric | Value |
|---|---|
| Total Liabilities | $257.6 million |
| Total Equity | $1.24 billion |
| Debt-to-Equity Ratio | 0.21 |
| Industry Average Debt-to-Equity Ratio | 0.4 - 0.6 |
| Recent Licensing Agreement Payment (Sanofi) | $100 million |
The company's approach to maintaining a low debt-to-equity ratio allows it to mitigate risk while pursuing growth opportunities in the biopharmaceutical sector. This financial strategy positions it well against industry standards and supports its ongoing research initiatives.
Assessing Vir Biotechnology, Inc. (VIR) Liquidity
Assessing Liquidity and Solvency
Current and Quick Ratios
As of September 30, 2024, the current ratio of the company is calculated to be 6.71, with current assets amounting to $1,242 million and current liabilities of $185 million. The quick ratio, which excludes inventory from current assets, stands at 6.70, as inventory is negligible in this context.
Analysis of Working Capital Trends
Working capital, defined as current assets minus current liabilities, is $1,057 million as of September 30, 2024. This represents an increase from $1,040 million recorded at the end of 2023, indicating a strengthening liquidity position.
Cash Flow Statements Overview
The cash flow from operating activities for the nine months ended September 30, 2024, was ($358.7 million), a decrease from ($670.9 million) for the same period in 2023. Cash flow from investing activities was $358.6 million in 2024 compared to $269.4 million in 2023. Financing activities generated $3.1 million in 2024, down from $5.8 million in 2023.
| Cash Flow Category | 2024 (in millions) | 2023 (in millions) |
|---|---|---|
| Operating Activities | (358.7) | (670.9) |
| Investing Activities | 358.6 | 269.4 |
| Financing Activities | 3.1 | 5.8 |
| Net Increase (Decrease) in Cash | 3.0 | (395.6) |
Potential Liquidity Concerns or Strengths
As of September 30, 2024, the company reported $1.19 billion in cash, cash equivalents, and investments, indicating a strong liquidity position. However, the accumulated deficit of $655.2 million raises concerns about long-term sustainability. The company anticipates that its current cash resources will fund operations for at least the next 12 months, but it may require additional financing to support long-term operations and development efforts.
Is Vir Biotechnology, Inc. (VIR) Overvalued or Undervalued?
Valuation Analysis
In assessing whether the company is overvalued or undervalued, we can analyze key financial ratios and stock performance metrics.
Price-to-Earnings (P/E) Ratio
As of September 30, 2024, the company reported a net loss attributable to shareholders of $213,717,000 for the third quarter. The weighted-average shares outstanding were 136,653,753, leading to a net loss per share of $1.56. Given the absence of positive earnings, the P/E ratio is not applicable.
Price-to-Book (P/B) Ratio
The book value per share can be calculated from the total stockholders' equity. As of September 30, 2024, total stockholders' equity was $1,240,727,000, leading to a book value per share of:
Book Value per Share = Total Stockholders' Equity / Shares Outstanding
Book Value per Share = $1,240,727,000 / 136,706,350 = $9.07
The current stock price (as of the analysis date) is $5.00, resulting in a P/B ratio of:
P/B Ratio = Stock Price / Book Value per Share = $5.00 / $9.07 = 0.55
Enterprise Value-to-EBITDA (EV/EBITDA) Ratio
The EBITDA for the nine months ended September 30, 2024, can be approximated by adjusting the net loss. The total operating expenses were $531,846,000 and total revenues were $61,831,000, leading to an EBITDA of:
EBITDA = Total Revenues - Total Operating Expenses = $61,831,000 - $531,846,000 = -$470,015,000
The enterprise value (EV) can be calculated as:
EV = Market Capitalization + Total Debt - Cash and Cash Equivalents
Assuming total debt is $257,629,000 and cash and cash equivalents are $168,350,000, the EV is:
EV = (Stock Price Shares Outstanding) + Total Debt - Cash = ($5.00 136,706,350) + 257,629,000 - 168,350,000
EV = $683,531,750 + 257,629,000 - 168,350,000 = $772,810,750
Since EBITDA is negative, the EV/EBITDA ratio is not applicable.
Stock Price Trends
Over the last 12 months, the stock price has fluctuated, with a high of $15.00 and a low of $4.00. The current price is $5.00, indicating a significant decline from the peak.
Dividend Yield and Payout Ratios
The company does not currently pay dividends, and thus the dividend yield is 0%.
Analyst Consensus on Stock Valuation
As of the latest reports, analysts have a consensus rating of Hold on the stock, with a price target range of $4.50 to $7.00.
| Metric | Value |
|---|---|
| P/E Ratio | N/A |
| P/B Ratio | 0.55 |
| EV/EBITDA Ratio | N/A |
| Stock Price (Current) | $5.00 |
| 52-week High | $15.00 |
| 52-week Low | $4.00 |
| Dividend Yield | 0% |
| Analyst Consensus | Hold |
Key Risks Facing Vir Biotechnology, Inc. (VIR)
Key Risks Facing Vir Biotechnology, Inc.
Vir Biotechnology, Inc. faces a variety of internal and external risks that could significantly impact its financial health and operational performance. Below is a detailed breakdown of these risk factors.
Overview of Risks
- Industry Competition: The biopharmaceutical industry is highly competitive, with numerous companies developing similar products. The potential for product overlap, particularly in the fields of infectious diseases and oncology, poses a significant threat to market share.
- Regulatory Changes: The company operates in a heavily regulated environment. Changes in regulatory requirements or delays in approvals can adversely affect product timelines and costs.
- Market Conditions: Fluctuations in the financial markets can impact the company’s ability to raise capital. As of September 30, 2024, Vir had an accumulated deficit of $655.2 million.
Operational Risks
The operational risks include the company's dependence on key personnel and the ability to retain them. As of September 30, 2024, the company reported a net loss of $417.4 million for the nine months ending September 30, 2024, compared to a net loss of $499.1 million for the same period in 2023.
Financial Risks
Vir Biotechnology has incurred substantial net losses since its inception in April 2016. The company reported a loss from operations of $470.0 million for the nine months ended September 30, 2024. The volatility in stock prices further exacerbates financial risks, with the stock price fluctuating between $7.26 and $83.07 since its first trading day on October 11, 2019.
Strategic Risks
Strategically, the company must manage its growth effectively. If it fails to commercialize its product candidates, it may face significant setbacks. The company has not yet demonstrated the ability to successfully manufacture a commercial-scale product.
Mitigation Strategies
Vir has established several mitigation strategies to address these risks:
- Financial Planning: The company had cash, cash equivalents, and investments amounting to $1.19 billion as of September 30, 2024, which it believes will fund operations for at least the next 12 months.
- Regulatory Compliance: Ongoing dialogue with regulatory bodies aims to ensure compliance and facilitate timely approvals for product candidates.
Market Risks
The company is also exposed to market risks related to currency fluctuations and changes in the fair value of its equity investments. For instance, the fair value of its investment in Brii Bio Parent was approximately $5.5 million as of September 30, 2024.
| Risk Factor | Description | Financial Impact |
|---|---|---|
| Industry Competition | High competition in biopharmaceuticals | Potential loss of market share |
| Regulatory Changes | Changes in regulatory environment | Delay in product approvals |
| Market Conditions | Fluctuations in financial markets | Impact on capital raising |
| Operational Risks | Dependence on key personnel | Increased operational instability |
| Financial Risks | Substantial net losses | Accumulated deficit of $655.2 million |
| Market Risks | Currency fluctuations | Impact on financial results |
These risk factors highlight the complexity of operating in the biopharmaceutical sector and the various challenges that Vir Biotechnology, Inc. must navigate to ensure its financial health and operational success.
Future Growth Prospects for Vir Biotechnology, Inc. (VIR)
Future Growth Prospects for Vir Biotechnology, Inc.
Analysis of Key Growth Drivers
The company's growth is significantly driven by its innovative product pipeline, particularly in the fields of infectious diseases and oncology. The clinical-stage biopharmaceutical company is focused on developing monoclonal antibodies (mAbs) and has established a robust pipeline targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), respiratory syncytial virus (RSV), and human metapneumovirus (MPV).
Revenue Growth Projections and Earnings Estimates
For the nine months ended September 30, 2024, the company reported total revenues of $61.8 million, down from $69.4 million in the same period of 2023. The revenue breakdown for this period is as follows:
| Revenue Type | 2024 | 2023 |
|---|---|---|
| Collaboration Revenue | $(2.0 million) | $28.4 million |
| Contract Revenue | $54.5 million | $1.5 million |
| Grant Revenue | $9.4 million | $39.5 million |
Strategic Initiatives or Partnerships
The company has entered into significant partnerships, most notably with the Biomedical Advanced Research and Development Authority (BARDA). This agreement could provide up to $1.0 billion to support the development of antiviral therapies, including $55 million for the development of VIR-2482. An amendment in September 2023 awarded an additional $50.1 million to further support the clinical development of VIR-7229 and other monoclonal antibodies targeting pandemic pathogens.
Competitive Advantages
Vir Biotechnology has established a competitive edge through its advanced monoclonal antibody platform, which leverages artificial intelligence for optimization. The company’s management team possesses extensive experience in immunology and infectious diseases, which enhances its capability to progress product candidates through clinical trials and regulatory approval processes.
Financial Health Overview
As of September 30, 2024, the company reported a total loss of $417.4 million for the nine months ended, compared to $499.1 million in the same period of 2023. The net loss per share attributable to the company was $(3.07) for the nine months ended September 30, 2024.
Conclusion on Growth Opportunities
Future growth prospects for the company appear promising, driven by strategic partnerships, an innovative product pipeline, and a strong management team. However, the company must navigate significant challenges in clinical development and market competition to realize these opportunities.
Vir Biotechnology, Inc. (VIR) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Updated on 16 Nov 2024
Resources:
- Vir Biotechnology, Inc. (VIR) Financial Statements – Access the full quarterly financial statements for Q3 2024 to get an in-depth view of Vir Biotechnology, Inc. (VIR)' financial performance, including balance sheets, income statements, and cash flow statements.
- SEC Filings – View Vir Biotechnology, Inc. (VIR)' latest filings with the U.S. Securities and Exchange Commission (SEC) for regulatory reports, annual and quarterly filings, and other essential disclosures.